Results

Total Results: over 10,000 records

Showing results for "stage".

261. Childbirth | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/childbirth
     July 12, 2016 - The first stage begins with contractions. … The second stage is the active stage, in which you begin to push downward. … In the third stage, you deliver the placenta.

262. Pqi 10 Dehydration Admission Rate (pdf file)
     qualityindicators.ahrq.gov/Downloads/Modules/PQI/v2018/TechSpecs/PQI_10_Dehydration_Admission_Rate.pdf
     June 01, 2018 - Chronic renal failure diagnosis codes: (CRENLFD) I120 Hypertensive chronic kidney disease with stage … 5 chronic kidney disease or end stage renal disease N185 Chronic kidney disease, stage 5 I1311 … Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney … disease, or end stage renal disease N186 End stage renal disease I132 Hypertensive heart and chronic … kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease

263. Comparative Effectiveness of Antihypertensive Therapies on Cardiovascular Disease Outcomes In End-Stage Renal Disease | Effective Health Care Program
     effectivehealthcare.ahrq.gov/products/renal-disease-therapies
     March 31, 2011 - Comparative Effectiveness of Antihypertensive Therapies on Cardiovascular Disease Outcomes In End-Stage … Comparative Effectiveness of Antihypertensive Therapies on Cardiovascular Disease Outcomes In End-Stage

264. Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage Renal Disease | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/renal-disease-iron/abstract
     November 01, 2017 - Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage … Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage … Timeline Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage … Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage

265. Opportunities for Future Measurement of Care Coordination with Electronic Data | Agency for Healthcare Research and Quality
     www.ahrq.gov/research/findings/final-reports/prospectscare/prospects2.html
     July 01, 2018 - Tables 1 , 2 , and 3 list Stage I and Stage II Meaningful Use measures that contain data elements … Stage I of Meaningful Use also requires reporting of Clinical Quality Measures using EHR data. … be delayed until 2014 for those sites that attest to Stage I Meaningful Use in 2011. … Thus, although specification of Stage II Meaningful Use elements will be available much sooner (final … I and Stage II measures, would be insufficient to facilitate broader quality measurement.

266. Coaching-Material (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/hais/tools/ambulatory-surgery/sections/implementation/training-tools/coaching-material.docx
     May 01, 2017 - · Three-Part Question* (1 min 24) Putting Coaching Teams Into Action* · Slides 28-42 · Setting the Stage … Materials: Slides 28-42, Setting the Stage video, Open-ended Question video, Three-Part Question video … Materials: Slides 28-42, Setting the Stage video, Open-Ended Question video, Three-Part Question video

267. Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage Renal Disease | Effective Health Care Program
     effectivehealthcare.ahrq.gov/products/renal-disease-iron
     January 24, 2012 - Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage Renal … Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage

268. Comparative Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage Renal Disease (ESRD) | Effective Health Care Program
     effectivehealthcare.ahrq.gov/products/renal-disease-anemia
     March 31, 2011 - Comparative Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage … Comparative Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage

269. Final Research Plan: Skin Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/skin-cancer-screening
     March 25, 2021 - routine skin cancer screening lead to higher rates of detection of precancerous lesions or earlier stage … What is the association between detection of precancerous lesions or earlier stage skin cancer and morbidity … However, outcomes for KQ 2 now are focused on stage or lesion thickness at detection of skin cancer or … 1, 2: No visual skin examination KQ 2: Usual care, (e.g. lesion-directed examination) KQ 4: Stage … USPSTF clarified the wording of KQs 2 and 4 to more clearly delineate precancerous lesions from early-stage

270. Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs | Effective Health Care Program
     effectivehealthcare.ahrq.gov/products/chronic-kidney-disease-anemia
     January 14, 2013 - Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future … Review Archived Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage

271. Psn-Pdf (pdf file)
     psnet.ahrq.gov/node/36592/psn-pdf
     May 08, 2018 - Anticoagulant safety takes center stage in 2007. May 8, 2018 ISMP Medication Safety Alert! … https://psnet.ahrq.gov/issue/anticoagulant-safety-takes-center-stage-2007 This article, which launches … https://psnet.ahrq.gov/issue/anticoagulant-safety-takes-center-stage-2007

272. Screening for and Management of Chronic Kidney Disease Stages 1-3 | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/kidney-disease-medicine/research-protocol
     July 28, 2010 - Within this framework, K/DOQI then classified CKD into five stages as follows: Stage 1: Kidney damage … with GFR >90 mL/min/1.73 m 2 Stage 2: Kidney damage with GFR 60-89 mL/min/1.73 m 2 Stage 3: GFR … 30-59 mL/min/1.73 m 2 Stage 4: GFR 15-29 mL/min/1.73 m 2 Stage 5: GFR <15 mL/min/1.73 m 2 or kidney … (2) Albuminuria stages should be added within each GFR stage (urinary ACR <30 mg/g, 30-299 mg/g, or … stage 2 CKD, 7.7% (15.5 million) in stage 3 CKD, and 0.4% (0.7 million) in stage 4 CKD. 3 U.S. prevalence

273. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/kidney-disease-medicine_research-protocol.pdf
     November 01, 2010 - 2: Kidney damage with GFR 60-89 mL/min/1.73 m2 • Stage 3: GFR 30-59 mL/min/1.73 m2 • Stage 4: GFR … (2) Albuminuria stages should be added within each GFR stage (urinary ACR <30 mg/g, 30-299 mg/g … Epidemiology of CKD Based on the K/DOQI CKD definition and stage classification, and utilizing a … Of the population,1.8% (3.6 million) individuals were classified in stage 1 CKD, 3.2% (6.5 million) … in stage 2 CKD, 7.7% (15.5 million) in stage 3 CKD, and 0.4% (0.7 million) in stage 4 CKD.3 U.S.

274. Evidence Report on the (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/kidney-disease-medicine_research-protocol.pdf
     November 01, 2010 - 2: Kidney damage with GFR 60-89 mL/min/1.73 m2 • Stage 3: GFR 30-59 mL/min/1.73 m2 • Stage 4: GFR … (2) Albuminuria stages should be added within each GFR stage (urinary ACR <30 mg/g, 30-299 mg/g … Epidemiology of CKD Based on the K/DOQI CKD definition and stage classification, and utilizing a … Of the population,1.8% (3.6 million) individuals were classified in stage 1 CKD, 3.2% (6.5 million) … in stage 2 CKD, 7.7% (15.5 million) in stage 3 CKD, and 0.4% (0.7 million) in stage 4 CKD.3 U.S.

275. The Nature, Characteristics and Patterns of Perinatal Critical Events Teams (pdf file)
     ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol3/Advances-Riley_58.pdf
     April 02, 2008 - Kappa (к) scores for each measure of the observation instrument Behavior marker Stage 1 Stage 2 Stage … 3 Stage 4 Stage 5 Stage 6 Situational awareness 1.00 0.79 0.86 1.00 0.75 0.89 Shared mental model … • Stage 2: Identification of clinical crisis. • Stage 3: Declaration of emergency. … • Stage 4: Induction. • Stage 5: Surgical procedure. • Stage 6: Infant resuscitation. … Proportion of “excellent” behavioral markers by stage (%) Behavior marker Stage 1 Stage 2 Stage 3 Stage

276. Lung-Cancer-Nonsurgical-Therapies Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/lung-cancer-nonsurgical-therapies_executive.pdf
     June 01, 2013 - 1 Comparative Effectiveness Review Number 112 Local Nonsurgical Therapies for Stage I and Symptomatic … I, stage II, and selected stage III tumors) • Potentially operable or inoperable locally (T3–T4) … Several radiotherapy modalities have been used to treat patients with stage I NSCLC. … Surgery is the standard of care for eligible patients with stage I NSCLC. … The treatment of early-stage disease. Semin Radiat Oncol. 2010 Jul;20(3):178-85.

277. Lung-Cancer-Nonsurgical-Therapies Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/lung-cancer-nonsurgical-therapies_executive.pdf
     June 01, 2013 - 1 Comparative Effectiveness Review Number 112 Local Nonsurgical Therapies for Stage I and Symptomatic … I, stage II, and selected stage III tumors) • Potentially operable or inoperable locally (T3–T4) … Several radiotherapy modalities have been used to treat patients with stage I NSCLC. … Surgery is the standard of care for eligible patients with stage I NSCLC. … The treatment of early-stage disease. Semin Radiat Oncol. 2010 Jul;20(3):178-85.

278. Psn-Pdf (pdf file)
     psnet.ahrq.gov/node/37921/psn-pdf
     June 17, 2014 - High Quality Care for All: NHS Next Stage Review Final Report. June 17, 2014 Darzi A.  … https://psnet.ahrq.gov/issue/high-quality-care-all-nhs-next-stage-review-final-report This report outlines … https://psnet.ahrq.gov/issue/high-quality-care-all-nhs-next-stage-review-final-report

279. Disposition of Comments for Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/lung-cancer-nonsurgical-therapies_disposition-comments.pdf
     June 12, 2013 - Disposition of Comments for Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell … The CER is about local, nonsurgical interventions for stage I NSCLC. … There is a lack of analysis for RFA of medically inoperable stage I NSCLC. … Stereotactic body radiation therapy for inoperable early stage lung cancer. … , not “local therapies for stage I” lung cancer as stated.

280. Disposition of Comments for Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/lung-cancer-nonsurgical-therapies_disposition-comments.pdf
     June 12, 2013 - Disposition of Comments for Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell … The CER is about local, nonsurgical interventions for stage I NSCLC. … There is a lack of analysis for RFA of medically inoperable stage I NSCLC. … Stereotactic body radiation therapy for inoperable early stage lung cancer. … , not “local therapies for stage I” lung cancer as stated.